Wexford Capital’s Cogent Biosciences COGT Stock Holding History

Wexford Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,000	Closed	-$293K	–	236
2023 Q3	$293K	Hold	30,000	–	–	0.06%	155
2023 Q2	$355K	Hold	30,000	–	–	0.07%	132
2023 Q1	$324K	Hold	30,000	–	–	0.07%	130
2022 Q4	$347K	Hold	30,000	–	–	0.07%	86
2022 Q3	$448K	Sell	30,000 -30,000	-50%	-$411K	0.14%	87
2022 Q2	$541	Buy	60,000 +40,000	+200%	+$273K	0.03%	107
2022 Q1	$150	Hold	20,000	–	–	0.01%	146
2021 Q4	$172	Buy	+20,000	New	+$174K	0.01%	179
2021 Q2	$162K	Hold	20,000	–	–	0.02%	157
2021 Q1	$176K	Hold	20,000	–	–	0.03%	179
2020 Q4	$225K	Buy	+20,000	New	+$220K	0.04%	150

Other funds holding COGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wexford Capital's COGT Position: Q4 2023 in Review

Wexford Capital sold out of Cogent Biosciences (COGT) in Q4 2023, closing a stake of 30,000 shares — an estimated $293K sold.

Wexford Capital first reported a position in COGT in Q4 2020 and held it in 11 quarters. The position peaked at $448K in Q3 2022. 144 funds tracked by Wall St. Rank hold COGT as of Q4 2023.

Wexford Capital reported no remaining Cogent Biosciences position as of Q4 2023 after selling out during the quarter.
Wexford Capital sold 30,000 Cogent Biosciences shares in Q4 2023, an estimated $293K.
Wexford Capital first reported a position in Cogent Biosciences in Q4 2020 and held it in 11 quarters.
Wexford Capital's Cogent Biosciences position peaked at $448K in Q3 2022.
144 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2023.

Based on Wexford Capital's 13F filing for Q4 2023, filed 15 Feb 2024.